UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 10-Q
X QUARTERLY
REPORT PURSUANT TO SECTION 13 OR 15(d)
OF THE SECURITIES EXCHANGE ACT OF 1934
For the quarterly period ended April 1, 2007
OR
TRANSITION REPORT
PURSUANT TO SECTION 13
OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
For the transition
period from________to_______
COMMISSION FILE
NUMBER 1-3619
----
PFIZER INC.
(Exact name of registrant as specified in its charter)
DELAWARE
(State of Incorporation)
13-5315170
(I.R.S. Employer Identification No.)
235
East 42nd Street, New York, New York 10017
(Address of principal executive offices) (zip
code)
(212) 573-2323
(Registrant's telephone number)
Indicate by check mark whether the registrant (1) has
filed all reports required to be filed by Section 13 or 15(d) of the
Securities Exchange Act of 1934 during the preceding 12 months (or for such
shorter period that the registrant was required to file such reports) and (2)
has been subject to such filing requirements for the past 90 days.
YES X NO
Indicate by check mark whether the registrant is a large
accelerated filer, an accelerated filer, or a non-accelerated filer. See
definition of "accelerated filer and large accelerated filer" in
Rule 12b-2 of the Exchange Act (Check one):
Large accelerated filer X
Accelerated filer Non-accelerated
filer
Indicate by check mark whether the registrant is a shell
company (as defined in Rule 12b-2 of the Exchange Act).
YES NO X
At May 1, 2007, 7,018,262,990 shares of the issuer's
voting common stock were outstanding.
FORM 10-Q
For the Quarter
Ended
April 1, 2007
Table
of Contents
PART I. FINANCIAL
INFORMATION
Page
Item 1.
Financial Statements
Condensed
Consolidated Statements of Income for the three months ended April 1, 2007,
and April 2, 2006
Condensed
Consolidated Balance Sheets as of April 1, 2007, and December 31, 2006
Condensed
Consolidated Statements of Cash Flows for the three months ended April 1,
2007, and April 2, 2006
Notes to
Condensed Consolidated Financial Statements
Review Report
of Independent Registered Public Accounting Firm
17
Item 2.
Management's
Discussion and Analysis of Financial Condition and Results of Operations
18
Item 3.
Quantitative
and Qualitative Disclosures About Market Risk
43
Item 4.
Controls and
Procedures
43
PART II. OTHER
INFORMATION
Item 1.
Legal
Proceedings
43
Item 1A.
Risk Factors
46
Item 2.
Unregistered
Sales of Equity Securities and Use of Proceeds
46
Item 3.
Defaults Upon
Senior Securities
46
Item 4.
Submission of
Matters to a Vote of Security Holders
47
Item 5.
Other
Information
48
Item 6.
Exhibits
48
Signature
49
PART
I - FINANCIAL INFORMATION
Item 1. Financial Statements.
PFIZER INC AND
SUBSIDIARY COMPANIES
CONDENSED CONSOLIDATED STATEMENTS OF INCOME
(UNAUDITED)
Three
Months Ended
(millions, except per common share
data)
April 1,
2007
April 2,
2006
Revenues
12,474
11,747
Costs and expenses:
Cost of sales(a)
1,887
1,671
Selling,
informational and administrative expenses(a)
3,361
3,395
Research and
development expenses(a)
1,665
1,543
Amortization of
intangible assets
815
825
Acquisition-related
in-process research and development charges
283
--
Restructuring
charges and acquisition-related costs
812
299
Other (income)/deductions - net
(402)
(256)
Income from
continuing operations before provision for taxes on income and minority
interests
4,053
4,270
Provision for
taxes on income
689
262
Minority
interests
Income from
continuing operations
3,361
4,006
Discontinued
operations:
Income from
discontinued operations - net of tax
--
102
Gains on sales
of discontinued operations - net of tax
31
Discontinued
operations - net of tax
31
105
Net income
3,392
4,111
Earnings per common share - basic:
Income from
continuing operations
0.48
0.55
Discontinued
operations - net of tax
--
0.01
Net income
0.48
0.56
Earnings per common share -
diluted:
Income from
continuing operations
0.48
0.55
Discontinued
operations - net of tax
--
0.01
Net income
0.48
0.56
Weighted-average
shares used to calculate earnings per common share:
Basic
7,051
7,314
Diluted
7,075
7,348
Cash dividends paid per common
share
0.29
0.24
(a)
Exclusive of amortization of
intangible assets, except as disclosed in Note 10B. Goodwill and
Other Intangible Assets: Other Intangible Assets.
See accompanying
Notes to Condensed Consolidated Financial Statements.
PFIZER
INC AND SUBSIDIARY COMPANIES
CONDENSED CONSOLIDATED BALANCE SHEETS
(UNAUDITED)
(millions
of dollars)
April 1,
2007*
Dec. 31,
2006**
ASSETS
Cash and cash equivalents
2,492
1,827
Short-term investments
19,978
25,886
Accounts receivable, less allowance
for doubtful accounts
10,455
9,392
Short-term loans
462
514
Inventories
5,694
6,111
Prepaid expenses and taxes
3,231
3,157
Assets of discontinued operations and
other assets held for sale
25
62
Total current assets
42,337
46,949
Long-term
investments and loans
4,817
3,892
Property, plant and equipment, less
accumulated depreciation
16,481
16,632
Goodwill
20,911
20,876
Identifiable
intangible assets, less accumulated amortization
23,501
24,350
Other assets,
deferred taxes and deferred charges
2,436
2,138
Total assets
110,483
114,837
LIABILITIES
AND SHAREHOLDERS' EQUITY
Short-term borrowings, including
current portion of long-term debt
2,638
2,434
Accounts payable
2,037
2,019
Dividends payable
2,055
Income taxes payable
533
6,466
Accrued compensation and related
items
1,679
1,903
Other current liabilities
6,412
6,510
Liabilities of discontinued operations
and other liabilities held for sale
--
Total current liabilities
13,301
21,389
Long-term debt
4,771
5,546
Pension benefit
obligations
3,387
3,632
Postretirement
benefit obligations
1,967
1,970
Deferred taxes
7,363
8,015
Other taxes
payable
4,568
--
Other
noncurrent liabilities
2,638
2,927
Total liabilities
37,995
43,479
Shareholders' Equity
Preferred stock
124
141
Common stock
441
441
Additional
paid-in capital
69,209
69,104
Employee
benefit trust, at fair value
(583)
(788)
Treasury stock
(49,255)
(46,740)
Retained
earnings
53,063
49,669
Accumulated
other comprehensive income
(511)
(469)
Total shareholders' equity
72,488
71,358
Total liabilities and shareholders'
equity
110,483
114,837
* Unaudited.
** Condensed from audited
financial statements.
See accompanying
Notes to Condensed Consolidated Financial Statements.
PFIZER INC AND
SUBSIDIARY COMPANIES
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS
(UNAUDITED)
Three
Months Ended
(millions of dollars)
April 1,
2007
April 2,
2006
Operating
Activities:
Net income
3,392
4,111
Adjustments to
reconcile net income to net cash provided by operating activities:
Depreciation
and amortization
1,271
1,351
Share-based
compensation expense
141
172
Acquisition-related
in-process research and development charges
283
--
Gains on
disposal of investments, products and product lines
(10)
(77)
Income from
discontinued operations
--
155
Gains on sales
of discontinued operations
(40)
(5)
Deferred taxes
from continuing operations
(268)
(309)
Other deferred
taxes
--
(5)
Other non-cash
adjustments
61
26
Changes in
assets and liabilities (net of businesses acquired and divested)
(3,587)
(1,458)
Net cash provided by operating
activities
1,243
3,961
Investing Activities:
Purchases of
property, plant and equipment
(329)
(418)
Purchases of
short-term investments
(5,617)
(2,735)
Proceeds from
redemptions of short-term investments
11,819
10,438
Purchases of
long-term investments
(1,158)
(216)
Proceeds from redemptions
of long-term investments
Purchases of other
assets
(2)
(35)
Proceeds from
sales of other assets
--
Proceeds from
the sales of businesses, products and product lines
Acquisitions,
net of cash acquired
(463)
(1,440)
Other investing
activities
(177)
Net cash provided by investing
activities
4,271
5,431
Financing Activities:
Increase in
short-term borrowings, net
162
826
Principal
payments on short-term borrowings
(729)
(8,056)
Proceeds from
issuances of long-term debt
19
1,035
Principal
payments on long-term debt
(58)
(1)
Purchases of
common stock
(2,500)
(1,000)
Cash dividends
paid
(2,032)
(1,743)
Stock option
transactions and other
290
173
Net cash used
in financing activities
(4,848)
(8,766)
Effect of exchange-rate
changes on cash and cash equivalents
(1)
(4)
Net increase/(decrease)
in cash and cash equivalents
665
622
Cash and cash
equivalents at beginning of period
1,827
2,247
Cash and cash
equivalents at end of period
2,492
2,869
Supplemental
Cash Flow Information:
Cash paid
during the period for:
Income taxes
2,424
640
Interest
170
213
See accompanying
Notes to Condensed Consolidated Financial Statements.
PFIZER
INC AND SUBSIDIARY COMPANIES
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(UNAUDITED)
Note 1. Basis of
Presentation
We prepared the condensed
consolidated financial statements following the requirements of the Securities
and Exchange Commission (SEC) for interim reporting. As permitted under those
rules, certain footnotes or other financial information that are normally
required by accounting principles generally accepted in the United States of
America (GAAP) can be condensed or omitted. Balance sheet amounts and operating
results for subsidiaries operating outside the U.S. are as of and for the
three-month periods ended February 25, 2007, and February 26, 2006.
We made certain reclassifications to
the 2006 condensed consolidated financial statements to conform to the 2007 presentation.
These reclassifications are primarily related to discontinued operations (see Note
4. Discontinued Operations).
Revenues, expenses, assets and
liabilities can vary during each quarter of the year. Therefore, the results
and trends in these interim financial statements may not be representative of
those for the full year.
We are responsible for the unaudited
financial statements included in this document. The financial statements
include all normal and recurring adjustments that are considered necessary for
the fair presentation of our financial position and operating results.
The information included in this
Quarterly Report on Form 10-Q should be read in conjunction with the
consolidated financial statements and accompanying notes included in Pfizer's
Annual Report on Form 10-K for the year ended December 31, 2006.
Note 2. Adoption of New
Accounting Policy
As of January 1, 2007, we adopted the provisions of Financial Accounting
Standards Board (FASB) Interpretation No. 48 (FIN 48), Accounting for
Uncertainty in Income Taxes, an interpretation of SFAS 109, Accounting for
Income Taxes, and changed our policy related to the accounting for
income tax contingencies. To understand the cumulative effect of this
accounting change, see Note 6A. Taxes on Income: Adoption of
New Accounting Standard.
We continue to account for income tax
contingencies using a benefit recognition model. Beginning January
1, 2007, if we consider that a tax position is 'more likely than not' of being
sustained upon audit, based solely on the technical merits of the position, we
recognize the benefit. We measure the benefit by determining the amount that is
greater than 50% likely of being realized upon settlement, presuming that the
tax position is examined by the appropriate taxing authority that has full
knowledge of all relevant information. These assessments can be complex and we
often obtain assistance from external advisors.
Under the benefit recognition model, if our initial assessment
fails to result in the recognition of a tax benefit, we regularly monitor our
position and subsequently recognize the tax benefit if there are changes in tax
law or analogous case law that sufficiently raise the likelihood of prevailing
on the technical merits of the position to more likely than not; if the statute
of limitations expires; or if there is a completion of an audit resulting in a
settlement of that tax year with the appropriate agency.
Uncertain tax positions, represented by liabilities on our balance sheet,
are now classified as current only when we expect to pay cash within the next
12 months. Interest and penalties, if any, continue to be recorded in Provision
for taxes on income and are classified on the balance sheet with the
related tax liability.
Historically, our policy had been to account for income tax contingencies
based on whether we determined our tax position to be 'probable' under current
tax law of being sustained, as well as an analysis of potential outcomes under
a given set of facts and circumstances. In addition, we previously
considered all tax liabilities as current once the associated tax year was
under audit.
Note 3. Acquisitions
In the first quarter of 2007, we
acquired BioRexis Pharmaceutical Corp., a privately held biopharmaceutical
company with a number of diabetes candidates and a novel technology platform
for developing new protein drug candidates, and Embrex, Inc., an animal health
company that possesses a unique vaccine delivery system known as Inovoject, which
enables baby chicks to be vaccinated while inside their eggs. In connection
with these and other small acquisitions, we recorded $283 million in Acquisition-related
in-process research and development charges.
On February 28, 2006, we completed
the acquisition of the sanofi-aventis worldwide rights, including patent rights
and production technology, to manufacture and sell Exubera, an inhaled form of
insulin for use in adults with type 1 and type 2 diabetes, and the
insulin-production business and facilities located in Frankfurt, Germany,
previously jointly owned by Pfizer and sanofi-aventis, for approximately $1.4 billion
(including transaction costs). In 2006, in connection with the acquisition, as
part of our final purchase price allocation, we recorded $1.0 billion of
developed technology rights, $218 million of inventory and $166 million
of Goodwill, all of which have been allocated to our Pharmaceutical segment.
The amortization of the developed technology rights is primarily included in Cost
of sales. Prior to the acquisition, in connection with our collaboration
agreement with sanofi-aventis, we recorded a research and development milestone
due to us from sanofi-aventis of $118 million ($71 million, after
tax) in the first quarter of 2006 in Research and development expenses
upon the approval of Exubera in January 2006 by the Food and Drug
Administration (FDA).
Note 4. Discontinued
Operations
The following amounts, primarily related
to our Consumer Healthcare business which was sold in December 2006 for $16.6 billion,
have been segregated from continuing operations and included in Discontinued
operations - net of tax in the condensed consolidated statements of income:
First
Quarter
(in millions)
April 1,
2007
April 2,
2006
Revenues
--
919
Pre-tax income
--
155
Provision for
taxes on income
--
(53)
Income from operations
of discontinued businesses - net of tax
--
102
Pre-tax gains on sales of
discontinued businesses
40
Provision for taxes on gains
(9)
(2)
Gains on sales
of discontinued operations - net of tax
31
Discontinued operations - net of
tax
31
105
For a period of time, we will
continue to generate cash flows and to report income statement activity in
continuing operations that are associated with our former Consumer Healthcare
business. The activities that give rise to these impacts are transitional in
nature and generally result from agreements that ensure and facilitate the
orderly transfer of business operations to the new owner. Included in
continuing operations for the first quarter of 2007 are the following amounts
associated with these transition service agreements that will no longer occur
after the full transfer of activities to the new owner: Revenues ($44 million),
Cost of sales ($35 million), Selling, informational and
administrative expense ($2 million) and Other
(income)/deduction-net ($2 million income).
Note 5. Adapting to
Scale Productivity Initiative
We incurred the following costs in
connection with our Adapting to Scale (AtS) productivity initiative, which was launched
in early 2005 and broadened in October 2006:
First
Quarter
(millions
of dollars)
April 1,
2007
April 2,
2006
Implementation
costs(a)
174
185
Restructuring
charges(b)
795
294
Total AtS costs
969
479
(a)
For
the first quarter of 2007, included in Cost of sales ($94 million),
Selling, informational and administrative expenses ($49 million),
and Research and development expenses ($31 million). For
the first quarter of 2006, included in Cost of sales ($124 million),
Selling, informational and administrative expenses ($39 million) and
Research and development expenses ($22 million).
(b)
Included
in Restructuring charges and acquisition-related costs.
Through April 1, 2007, the
restructuring charges primarily relate to our plant network optimization
efforts and the restructuring of our U.S. marketing and worldwide research and
development operations, while the implementation costs primarily relate to system
and process standardization, as well as the expansion of shared services.
The components of restructuring charges
associated with AtS follow:
(millions
of dollars)
Costs
Incurred
Through
April 1,
2007
Utilization
Through
April 1,
2007
Accrual
as of
April 1,
2007
(a)
Employee
termination costs
1,843
1,154
689
Asset
impairments
513
513
Other
173
107
66
Total
2,529
1,774
755
(a)
Included
in Other current liabilities and Other noncurrent liabilities.
During the first quarter of 2007, we
expensed $731 million for Employee termination costs, $23 million
for Asset impairments and $41 million in Other. Through April 1,
2007, Employee termination costs represent the expected reduction
of the workforce by 13,568 employees, mainly in research, manufacturing
and sales. Approximately 8,510 employees were terminated as of April 1,
2007. Employee termination costs include accrued severance benefits,
pension and postretirement benefits. Asset impairments primarily include
charges to write down property, plant and equipment. Other primarily
includes costs to exit certain activities.
Note 6. Taxes on
Income
A. Adoption of New Accounting Standard
As of January 1, 2007, we adopted the provisions of FIN 48, Accounting
for Uncertainty in Income Taxes, an interpretation of SFAS 109, Accounting
for Income Taxes. See Note 2. Adoption of New Accounting Policy,
for a full description of our accounting policy related to the accounting for
income tax contingencies. As a result of the
implementation of FIN 48, we reduced our existing liabilities for uncertain tax
positions by approximately $11 million, which has been recorded as a
direct adjustment to the opening balance of Retained earnings, and changed
the classification of virtually all uncertain tax positions, including the
associated accrued interest, from current to noncurrent.
B. Taxes on Income
On January 23, 2006, the Internal
Revenue Service (IRS) issued final regulations on Statutory Mergers and
Consolidations, which impacted certain prior-period transactions. In the first
quarter of 2006, we recorded a tax benefit of $217 million, reflecting the
total impact of these regulations.
On January 25, 2006, we were notified by the IRS Appeals Division that a
resolution had been reached on the matter that we were in the process of
appealing related to the tax deductibility of an acquisition-related breakup
fee paid by Warner-Lambert Company in 2000. As a result, in the first quarter
of 2006, we recorded a tax benefit of approximately $441 million related
to the resolution of this issue.